The 2013 SFRBM discovery award: Selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment

Free Radical Biology and Medicine

Volumn 74, Issue , 2014, Pages 157-174

  Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

2013 SFRBM Discovery Award; Alzheimer disease (AD) and its earlier forms (amnestic MCI and preclinical AD); A (1 42) associated oxidative stress; Chemotherapy induced cognitive impairment (" chemobrain"); Plasma derived elevated TNF and its sequela in brain; Redox proteomics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTINEOPLASTIC AGENT; PEPTIDE FRAGMENT;

ADVERSE DRUG REACTION; ALZHEIMER DISEASE; ANIMAL; CHEMICALLY INDUCED; COGNITIVE DEFECT; DISEASE MODEL; HUMAN; LIPID PEROXIDATION; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN MULTIMERIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIPID PEROXIDATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION;

EID: 84904960454     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.06.006     Document Type: Review

References (181)

1. B. Halliwell, and J. Gutteridge Free radicals in biology and medicine 2007 Oxford University Press 704
2. D.A. Butterfield, and E.R. Stadman Protein oxidation processes in aging brain Adv. Cell Aging Gerontol 2 1997 161 191
3. J.S. Beckman, J. Chen, H. Ischiropoulos, and J.P. Crow Oxidative chemistry (Pubitemid 24177546)
4. D.A. Butterfield, M.L. Bader Lange, and R. Sultana Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer?s disease Biochim. Biophys. Acta 1801 2010 924 929
5. H. Esterbauer, R.J. Schaur, and H. Zollner Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes Free Radic. Biol. Med. 11 1991 81 128 (Pubitemid 121003917)
6. D.A. Butterfield, M. Perluigi, T. Reed, T. Muharib, C.P. Hughes, R.A. Robinson, and R. Sultana Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications Antioxid. Redox Signal. 17 2012 1610 1655
7. Butterfield, D. A.; Di Domenico, F.; Robinson, R. A. S. Mass spectrometry and redox proteomics: applications in disease. Mass Spectrom. Rev. 33:277-301; 2014
8. D.A. Butterfield, and I. Dalle-Donne Redox proteomics: from protein modifications to cellular dysfunction and disease Mass Spectrom. Rev. 33 2014 1 6
9. P.T. Nelson, H. Braak, and W.R. Markesbery Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship J. Neuropathol. Exp. Neurol. 68 2009 1 14
10. D.J. Alzheimer?s Selkoe disease: genotypes, phenotypes, and treatments Science 275 1997 630 631
11. S.W. Scheff, and D.A. Price Alzheimer?s disease-related alterations in synaptic density: neocortex and hippocampus J. Alzheimers Dis. 9 2006 101 115 (Pubitemid 44253303)
12. R.C. Petersen, B. Caracciolo, C. Brayne, S. Gauthier, V. Jelic, and L. Fratiglioni Mild cognitive impairment: a concept in evolution J. Intern. Med. 275 2014 214 228
13. W.R. Markesbery Neuropathologic alterations in mild cognitive impairment: a review J. Alzheimers Dis. 19 2010 221 228
14. S.J. Vos, C. Xiong, P.J. Visser, M.S. Jasielec, J. Hassenstab, E.A. Grant, N.J. Cairns, J.C. Morris, D.M. Holtzman, and A.M. Fagan Preclinical Alzheimer?s disease and its outcome: a longitudinal cohort study Lancet Neurol. 12 2013 957 965
15. J. Hardy The amyloid hypothesis for Alzheimer?s disease: a critical reappraisal J. Neurochem. 110 2009 1129 1134
16. D.J. Alzheimer?s Selkoe disease is a synaptic failure Science 298 2002 789 791
17. W.L. Klein Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer?s disease? J. Alzheimers Dis. 33 Suppl. 1 2013 S49 S65
18. D.A. Butterfield Beta-amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer?s disease Chem. Res. Toxicol. 10 1997 495 506 (Pubitemid 27217205)
19. W.R. Markesbery Oxidative stress hypothesis in Alzheimer?s disease Free Radic. Biol. Med. 23 1997 134 147 (Pubitemid 27217017)
20. S. Varadarajan, S. Yatin, M. Aksenova, and D.A. Butterfield Review: Alzheimer?s amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity J. Struct. Biol. 130 2000 184 208
21. D.A. Butterfield, J. Drake, C. Pocernich, and A. Castegna Evidence of oxidative damage in Alzheimer?s disease brain: central role for amyloid beta-peptide Trends Mol. Med. 7 2001 548 554 (Pubitemid 33127140)
22. K. Hensley, N. Hall, R. Subramaniam, P. Cole, M. Harris, M. Aksenov, M. Aksenova, S.P. Gabbita, J.F. Wu, J.M. Carney, and D.A. Butterfield Brain regional correspondence between Alzheimer?s disease histopathology and biomarkers of protein oxidation J. Neurochem. 65 1995 2146 2156
23. C.M. Lauderback, J.M. Hackett, F.F. Huang, J.N. Keller, L.I. Szweda, W.R. Markesbery, and D.A. Butterfield The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer?s disease brain: the role of Abeta1-42 J. Neurochem. 78 2001 413 416 (Pubitemid 32664423)
24. D.A. Butterfield, and C.M. Lauderback Lipid peroxidation and protein oxidation in Alzheimer?s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress Free Radic. Biol. Med. 32 2002 1050 1060 (Pubitemid 34603342)
25. M. Perluigi, R. Coccia, and D.A. Butterfield 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies Antioxid. Redox Signal. 17 2012 1590 1609
26. J.N. Keller, K.B. Hanni, and W.R. Markesbery 4-hydroxynonenal increases neuronal susceptibility to oxidative stress J. Neurosci. Res. 58 1999 823 830
27. A. Castegna, V. Thongboonkerd, J.B. Klein, B. Lynn, W.R. Markesbery, and D.A. Butterfield Proteomic identification of nitrated proteins in Alzheimer?s disease brain J. Neurochem. 85 2003 1394 1401 (Pubitemid 36702552)
28. R. Sultana, H.F. Poon, J. Cai, W.M. Pierce, M. Merchant, J.B. Klein, W.R. Markesbery, and D.A. Butterfield Identification of nitrated proteins in Alzheimer?s disease brain using a redox proteomics approach Neurobiol. Dis. 22 2006 76 87
29. D.A. Butterfield, H.F. Poon St, D. Clair, J.N. Keller, W.M. Pierce, J.B. Klein, and W.R. Markesbery Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer?s disease Neurobiol. Dis. 22 2006 223 232
30. J.N. Keller, F.A. Schmitt, S.W. Scheff, Q. Ding, Q. Chen, D.A. Butterfield, and W.R. Markesbery Evidence of increased oxidative damage in subjects with mild cognitive impairment Neurology 64 2005 1152 1156
31. D.A. Butterfield, T. Reed, M. Perluigi, C. De Marco, R. Coccia, C. Cini, and R. Sultana Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment Neurosci. Lett. 397 2006 170 173
32. T. Reed, M. Perluigi, R. Sultana, W.M. Pierce, J.B. Klein, D.M. Turner, R. Coccia, W.R. Markesbery, and D.A. Butterfield Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer?s disease Neurobiol. Dis. 30 2008 107 120
33. D.A. Butterfield, T.T. Reed, M. Perluigi, C. De Marco, R. Coccia, J.N. Keller, W.R. Markesbery, and R. Sultana Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer?s disease Brain Res. 1148 2007 243 248 (Pubitemid 46602178)
34. T.T. Reed, W.M. Pierce, W.R. Markesbery, and D.A. Butterfield Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD Brain Res. 1274 2009 66 76
35. C.D. Aluise, R.A. Robinson, T.L. Beckett, M.P. Murphy, J. Cai, W.M. Pierce, W.R. Markesbery, and D.A. Butterfield Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics Neurobiol. Dis. 39 2010 221 228
36. M.A. Bradley, W.R. Markesbery, and M.A. Lovell Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease Free Radic. Biol. Med. 48 2010 1570 1576
37. A. Castegna, C.M. Lauderback, H. Mohmmad-Abdul, and D.A. Butterfield Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer?s disease Brain Res. 1004 2004 193 197 (Pubitemid 38368075)
38. H. Mohmmad Abdul, and D.A. Butterfield Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer?s disease Biochim. Biophys. Acta 1741 2005 140 148 (Pubitemid 40824999)
39. M.L. Bader Lange, G. Cenini, M. Piroddi, H.M. Abdul, R. Sultana, F. Galli, M Memo, and D.A. Butterfield Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease Neurobiol. Dis. 29 2008 456 464
40. M.L. Bader Lange St, D. Clair, W.R. Markesbery, C.M. Studzinski, M.P. Murphy, and D.A. Butterfield Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease Neurobiol. Dis. 38 2010 104 115
41. R. Sultana, M. Perluigi, S.F. Newman, W.M. Pierce, C. Cini, R. Coccia, and D.A. Butterfield Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer?s disease Antioxid. Redox Signal. 12 2010 327 336
42. D.A. Butterfield, A.M. Swomley, and R. Sultana Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression Antioxid. Redox Signal. 19 2013 823 835
43. D.A. Butterfield Proteomics: a new approach to investigate oxidative stress in Alzheimer?s disease brain Brain Res. 1000 2004 1 7 (Pubitemid 38446484)
44. D.A. Butterfield, D. Boyd-Kimball, and A. Castegna Proteomics in Alzheimer?s disease: insights into potential mechanisms of neurodegeneration J. Neurochem. 86 2003 1313 1327 (Pubitemid 37174249)
45. D.A. Butterfield, M. Perluigi, and R. Sultana Oxidative stress in Alzheimer?s disease brain: new insights from redox proteomics Eur. J. Pharmacol. 545 2006 39 50 (Pubitemid 44215876)
46. T.T. Reed, J. Owen, W.M. Pierce, A. Sebastian, P.G. Sullivan, and D.A. Butterfield Proteomic identification of nitrated brain proteins in traumatic brain-injured rats treated postinjury with gamma-glutamylcysteine ethyl ester: insights into the role of elevation of glutathione as a potential therapeutic strategy for traumatic brain injury J. Neurosci. Res. 87 2009 408 417
47. R. Sultana, D. Boyd-Kimball, H.F. Poon, J. Cai, W.M. Pierce, J.B. Klein, M. Merchant, W.R Markesbery, and D.A. Butterfield Redox proteomics identification of oxidized proteins in Alzheimer?s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD Neurobiol. Aging 27 2006 1564 1576 (Pubitemid 44344840)
48. R. Sultana, and D.A. Butterfield Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment J. Bioenerg. Biomembr. 41 2009 441 446
49. R. Sultana, M. Perluigi, and D. Allan Butterfield Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain Free Radic. Biol. Med. 62 2013 157 169
50. D.A. Butterfield, and M.L. Lange Multifunctional roles of enolase in Alzheimer?s disease brain: beyond altered glucose metabolism J. Neurochem. 111 2009 915 933
51. C.D. Aluise, R.A. Robinson, J. Cai, W.M. Pierce, W.R. Markesbery, and D.A. Butterfield Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer?s disease: insights into memory loss in MCI J. Alzheimers Dis. 23 2011 257 269
52. F. Di Domenico, R. Sultana, G.F. Tiu, N.N. Scheff, M. Perluigi, C. Cini, and D.A. Butterfield Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease Brain Res. 1333 2010 72 81
53. A. Castegna, M. Aksenov, M. Aksenova, V. Thongboonkerd, J.B. Klein, W.M. Pierce, R. Booze, W.R. Markesbery, and D.A. Butterfield Proteomic identification of oxidatively modified proteins in Alzheimer?s disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1 Free Radic. Biol. Med. 33 2002 562 571 (Pubitemid 34874977)
54. A. Castegna, M. Aksenov, V. Thongboonkerd, J.B. Klein, W.M. Pierce, R. Booze, W.R. Markesbery, and D.A. Butterfield Proteomic identification of oxidatively modified proteins in Alzheimer?s disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71 J. Neurochem. 82 2002 1524 1532
55. S.F. Newman, R. Sultana, M. Perluigi, R. Coccia, J. Cai, W.M. Pierce, J.B. Klein, D.M. Turner, and D.A. Butterfield An increase in S-glutathionylated proteins in the Alzheimer?s disease inferior parietal lobule, a proteomics approach J. Neurosci. Res. 85 2007 1506 1514 (Pubitemid 46724394)
56. R. Sultana, and D.A. Butterfield Oxidatively modified GST and MRP1 in Alzheimer?s disease brain: implications for accumulation of reactive lipid peroxidation products Neurochem. Res. 29 2004 2215 2220 (Pubitemid 40036893)
57. F. Di Domenico, M. Perluigi, C. Foppoli, C. Blarzino, R. Coccia, F. De Marco, D.A. Butterfield, and C. Cini Protective effect of ferulic acid ethyl ester against oxidative stress mediated by UVB irradiation in human epidermal melanocytes Free Radic. Res. 43 2009 365 375
58. R. Sultana, M. Perluigi, and D.A. Butterfield Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer?s disease: insights into mechanism of neurodegeneration from redox proteomics Antioxid. Redox Signal. 8 2006 2021 2037 (Pubitemid 46499264)
59. R. Sultana, M. Piroddi, F. Galli, and D.A. Butterfield Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment Neurochem. Res. 33 2008 2540 2546
60. R. Sultana, and D.A. Butterfield Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment Neurochem. Res. 32 2007 655 662 (Pubitemid 46481287)
61. J.T. Keeney, A.M. Swomley, J.L. Harris, A. Fiorini, M.I. Mitov, M. Perluigi, R. Sultana, and D.A. Butterfield Cell cycle proteins in brain in mild cognitive impairment: insights into progression to Alzheimer disease Neurotox. Res. 22 2012 220 230
62. G. Cenini, R. Sultana, M. Memo, and D.A. Butterfield Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer?s disease J. Cell. Mol. Med. 12 2008 987 994 (Pubitemid 351718076)
63. G. Cenini, R. Sultana, M. Memo, and D.A. Butterfield Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease Free Radic. Biol. Med. 45 2008 81 85
64. J.B. Owen, F. Di Domenico, R. Sultana, M. Perluigi, C. Cini, W.M. Pierce, and D.A. Butterfield Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer?s disease and mild cognitive impairment: implications for progression of AD J. Proteome Res. 8 2009 471 482
65. F. Di Domenico, J.B. Owen, R. Sultana, R.A. Sowell, M. Perluigi, C. Cini, J. Cai, W.M. Pierce, and DA. Butterfield The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer?s disease and mild cognitive impairment hippocampus and inferior parietal lobule: implications for disease pathogenesis and progression J. Neurosci. Res. 88 2010 3566 3577
66. D.A. Butterfield, and J.B. Owen Lectin-affinity chromatography brain glycoproteomics and Alzheimer disease: insights into protein alterations consistent with the pathology and progression of this dementing disorder Proteomics Clin. Appl. 5 2011 50 56
67. R. Sultana, W.A. Banks, and D.A. Butterfield Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer?s disease J. Neurosci. Res. 88 2010 469 477
68. J.B. Owen, R. Sultana, C.D. Aluise, M.A. Erickson, T.O. Price, G. Bu, W.A. Banks, and D.A. Butterfield Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain Free Radic. Biol. Med. 49 2010 1798 1803
69. E. Barone, F. Di Domenico, R. Sultana, R. Coccia, C. Mancuso, M. Perluigi, and D.A. Butterfield Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment Free Radic. Biol. Med. 52 2012 2292 2301
70. E. Barone, F. Di Domenico, G. Cenini, R. Sultana, C. Cini, P. Preziosi, M. Perluigi, C. Mancuso, and D.A. Butterfield Biliverdin reductase - a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment Biochim. Biophys. Acta 1812 2011 480 487
71. E. Barone, F. Di Domenico, C. Mancuso, and D.A. Butterfield The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it?s time for reconciliation Neurobiol. Dis. 62 2014 144 159
72. S.S. Hardas, R. Sultana, A.M. Clark, T.L. Beckett, L.I. Szweda, M.P. Murphy, and D.A. Butterfield Oxidative modification of lipoic acid by HNE in Alzheimer disease brain Redox Biol 1 2013 80 85
73. R. Subramaniam, F. Roediger, B. Jordan, M.P. Mattson, J.N. Keller, G. Waeg, and D.A. Butterfield The lipid peroxidation product, 4-hydroxy-2-trans- nonenal, alters the conformation of cortical synaptosomal membrane proteins J. Neurochem. 69 1997 1161 1169 (Pubitemid 27364837)
74. D.A. Butterfield, A. Gnjec, H.F. Poon, A. Castegna, W.M. Pierce, J.B. Klein, and R.N. Martins Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer?s disease: an initial assessment J. Alzheimers Dis. 10 2006 391 397
75. M. Perluigi, and D.A. Butterfield Oxidative stress and Down syndrome: a route toward Alzheimer-Like dementia Curr. Gerontol. Geriatr. Res 2012 2012 724904
76. G. Cenini, A.L. Dowling, T.L. Beckett, E. Barone, C. Mancuso, M.P. Murphy, H. Levine 3rd, I.T. Lott, F.A. Schmitt, D.A. Butterfield, and E. Head Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome Biochim. Biophys. Acta 1822 2012 130 138
77. M. Perluigi, and D.A. Butterfield The identification of protein biomarkers for oxidative stress in Down syndrome Expert Rev. Proteomics 8 2011 427 429
78. F. Di Domenico, R. Coccia, A. Cocciolo, M.P. Murphy, G. Cenini, E. Head, D.A. Butterfield, A. Giorgi, M.E. Schinina, C. Mancuso, C. Cini, and M. Perluigi Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer?s disease neuropathology: redox proteomics analysis of human brain Biochim. Biophys. Acta 1832 2013 1249 1259
79. M. Perluigi, F. Di Domenico, and D.A. Buttterfield Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics Proteomics Clin. Appl. 8 2014 73 85
80. M. Perluigi, F. di Domenico, A. Fiorini, A. Cocciolo, A. Giorgi, C. Foppoli, D.A. Butterfield, M. Giorlandino, C. Giorlandino, M.E. Schinina, and R. Coccia Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid Proteomics Clin. Appl. 5 2011 167 178
81. C.D. Aluise, R.A. Sowell, and D.A. Butterfield Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer?s disease Biochim. Biophys. Acta 1782 2008 549 558
82. F. Di Domenico, R. Coccia, D.A. Butterfield, and M. Perluigi Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits Biochim. Biophys. Acta 1814 2011 1785 1795
83. A. Cocciolo, F. Di Domenico, R. Coccia, A. Fiorini, J. Cai, W.M. Pierce, P. Mecocci, D.A. Butterfield, and M. Perluigi Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: insights from redox proteomics Free Radic. Biol. Med. 53 2012 1868 1876
84. F. Di Domenico, E. Barone, C. Mancuso, M. Perluigi, A. Cocciolo, P. Mecocci, D.A. Butterfield, and R. Coccia HO-1/BVR-a system analysis in plasma from probable Alzheimer?s disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease J. Alzheimers Dis. 32 2012 277 289
85. R. Sultana, P. Mecocci, F. Mangialasche, R. Cecchetti, M. Baglioni, and D.A. Butterfield Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer?s disease: insights into the role of oxidative stress in Alzheimer?s disease and initial investigations into a potential biomarker for this dementing disorder J. Alzheimers Dis. 24 2011 77 84
86. R. Sultana, M. Baglioni, R. Cecchetti, J. Cai, J.B. Klein, P. Bastiani, C. Ruggiero, P. Mecocci, and D.A. Butterfield Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease Free Radic. Biol. Med. 65c 2013 595 606
87. S.M. Yatin, S. Varadarajan, C.D. Link, and D.A. Butterfield In vitro and in vivo oxidative stress associated with Alzheimer?s amyloid beta-peptide (1-42) Neurobiol. Aging 20 1999 339 342 (325-330; discussion)
88. J. Drake, C.D. Link, and D.A. Butterfield Oxidative stress precedes fibrillar deposition of Alzheimer?s disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model Neurobiol. Aging 24 2003 415 420 (Pubitemid 36210870)
89. D. Boyd-Kimball, H.F. Poon, B.C. Lynn, J. Cai, W.M. Pierce Jr, J.B. Klein, J. Ferguson, C.D. Link, and D.A. Butterfield Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): implications for Alzheimer?s disease Neurobiol. Aging 27 2006 1239 1249 (Pubitemid 44067304)
90. H.M. Abdul, R. Sultana, D.K. St Clair, W.R. Markesbery, and D.A. Butterfield Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age Free Radic. Biol. Med. 45 2008 1420 1425
91. Q. Huang, C.D. Aluise, G. Joshi, R. Sultana, D.K. St Clair, W.R. Markesbery, and D.A. Butterfield Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment J. Neurosci. Res. 88 2010 2618 2629
92. R. Sultana, R.A. Robinson, F. Di Domenico, H.M. Abdul, D.K. St Clair, W.R. Markesbery, J. Cai, W.M. Pierce, and D.A. Butterfield Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age J. Proteomics 74 2011 2430 2440
93. 2, and kainic acid: implications for Alzheimer?s disease J. Neurochem. 96 2006 1322 1335
94. R.A. Robinson, M.B. Lange, R. Sultana, V. Galvan, J. Fombonne, O. Gorostiza, J. Zhang, G. Warrier, J. Cai, W.M. Pierce, D.E. Bredesen, and D.A. Butterfield Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-beta peptide of amyloid precursor protein Neuroscience 177 2011 207 222
95. R.A. Robinson, G. Joshi, Q. Huang, R. Sultana, A.S. Baker, J. Cai, W. Pierce, D.K. St Clair, W.R. Markesbery, and D.A. Butterfield Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid beta-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer?s disease Proteomics 11 2011 4243 4256
96. D. Boyd-Kimball, R. Sultana, H.F. Poon, B.C. Lynn, F. Casamenti, G. Pepeu, J.B. Klein, and D.A Butterfield Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer?s disease Neuroscience 132 2005 313 324 (Pubitemid 40417906)
97. P. Davies Loss of choline acetyltransferase activity in normal aging and in senile dementia Adv. Exp. Med. Biol 113 1978 251 256
98. A. Contestabile The history of the cholinergic hypothesis Behav. Brain Res. 221 2011 334 340
99. J.E. Morley, H.J. Armbrecht, S.A. Farr, and V.B. Kumar The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer?s disease Biochim. Biophys. Acta 1822 2012 650 656
100. D.A. Butterfield, and H.F. Poon The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer?s disease Exp. Gerontol. 40 2005 774 783 (Pubitemid 41416540)
101. S.A. Farr, H.F. Poon, D. Dogrukol-Ak, J. Drake, W.A. Banks, E. Eyerman, D.A. Butterfield, and J.E. Morley The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice J. Neurochem. 84 2003 1173 1183 (Pubitemid 36330669)
102. H.F. Poon, A. Castegna, S.A. Farr, V. Thongboonkerd, B.C. Lynn, W.A. Banks, J.E. Morley, J.B. Klein, and D.A. Butterfield Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain Neuroscience 126 2004 915 926 (Pubitemid 38780896)
103. H.F. Poon, S.A. Farr, V. Thongboonkerd, B.C. Lynn, W.A. Banks, J.E. Morley, J.B. Klein, and D.A. Butterfield Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders Neurochem. Int. 46 2005 159 168 (Pubitemid 41556623)
104. H.F. Poon, S.A. Farr, W.A. Banks, W.M. Pierce, J.B. Klein, J.E. Morley, and D.A. Butterfield Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Abeta region of amyloid precursor protein Brain Res. Mol. Brain Res. 138 2005 8 16 (Pubitemid 41032925)
105. A. Fiorini, R. Sultana, S. Forster, M. Perluigi, G. Cenini, C. Cini, J. Cai, J.B. Klein, S.A. Farr, M.L. Niehoff, J.E. Morley, V.B. Kumar, and D.A. Allan Butterfield Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: a proteomics study Free Radic. Biol. Med. 65c 2013 1 14
106. S.A. Farr, J.L. Ripley, R. Sultana, Z. Zhang, M.L. Niehoff, T.L. Platt, M.P. Murphy, J.E. Morley, V. Kumar, and D.A. Butterfield Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: involvement of transcription factor Nrf2 and implications for Alzheimer disease Free Radic. Biol. Med. 67 2014 387 395
107. C.W. Cotman, E. Head, B.A. Muggenburg, S. Zicker, and N.W. Milgram Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction Neurobiol. Aging 23 2002 809 818 (Pubitemid 35217705)
108. W.O. Opii, G. Joshi, E. Head, N.W. Milgram, B.A. Muggenburg, J.B. Klein, W.M. Pierce, C.W. Cotman, and D.A. Butterfield Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer?s disease Neurobiol. Aging 29 2008 51 70 (Pubitemid 350102715)
109. E. Barone, F. Di Domenico, and D.A. Butterfield Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets Biochem. Pharmacol. 88 2014 605 616
110. D.A. Butterfield, E. Barone, F. Di Domenico, G. Cenini, R. Sultana, M.P. Murphy, C. Mancuso, and E. Head Atorvastatin treatment in a dog preclinical model of Alzheimer?s disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain Int. J. Neuropsychopharmacol. 15 2012 981 987
111. E. Barone, C. Mancuso, F. Di Domenico, R. Sultana, M.P. Murphy, E. Head, and D.A. Butterfield Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease J. Neurochem. 120 2012 135 146
112. S.B. Martin, G. Cenini, E. Barone, A.L. Dowling, C. Mancuso, D.A. Butterfield, M.P. Murphy, and E. Head Coenzyme Q10 and cognition in atorvastatin treated dogs Neurosci. Lett. 501 2011 92 95
113. D.A. Butterfield, E. Barone, and C. Mancuso Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders Pharmacol. Res. 64 2011 180 186
114. C.M. Lauderback, J.M. Hackett, J.N. Keller, S. Varadarajan, L. Szweda, M. Kindy, W.R. Markesbery, and D.A. Butterfield Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer?s disease Biochemistry 40 2001 2548 2554 (Pubitemid 32171729)
115. C.M. Lauderback, J. Kanski, J.M. Hackett, N. Maeda, M.S. Kindy, and D.A. Butterfield Apolipoprotein E modulates Alzheimer?s Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner Brain Res. 924 2002 90 97 (Pubitemid 34017468)
116. D. Zhou, C.M. Lauderback, T. Yu, S.A. Brown, D.A. Butterfield, and J.S. Thompson D609 inhibits ionizing radiation-induced oxidative damage by acting as a potent antioxidant J. Pharmacol. Exp. Ther. 298 2001 103 109 (Pubitemid 32574515)
117. C.M. Lauderback, J. Drake, D. Zhou, J.M. Hackett, A. Castegna, J. Kanski, M. Tsoras, S. Varadarajan, and D.A. Butterfield Derivatives of xanthic acid are novel antioxidants: application to synaptosomes Free Radic. Res. 37 2003 355 365 (Pubitemid 36240398)
118. M. Perluigi, G. Joshi, R. Sultana, V. Calabrese, C. De Marco, R. Coccia, C. Cini, and D.A. Butterfield In vivo protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1-42-induced oxidative stress J. Neurosci. Res. 84 2006 418 426 (Pubitemid 44126294)
119. M.A. Ansari, G. Joshi, Q. Huang, W.O. Opii, H.M. Abdul, R. Sultana, and D.A. Butterfield In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer?s disease and other oxidative stress-related neurodegenerative disorders Free Radic. Biol. Med. 41 2006 1694 1703 (Pubitemid 44634240)
120. R. Sultana, A. Ravagna, H. Mohmmad-Abdul, V. Calabrese, and D.A. Butterfield Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity J. Neurochem. 92 2005 749 758 (Pubitemid 40229546)
121. D.A. Butterfield, T. Reed, S.F. Newman, and R. Sultana Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the
122. Swomley, A. M.; Forster, S.; Keeney, J. T.; Triplett, J.; Zhang, Z.Sultana, R.Butterfield, D.A.; Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim. Biophys. Acta; 2013.
123. M.E. Harris, K. Hensley, D.A. Butterfield, R.A. Leedle, and J.M. Carney Direct evidence of oxidative injury produced by the Alzheimer?s beta-amyloid peptide (1-40) in cultured hippocampal neurons Exp. Neurol. 131 1995 193 202
124. M.Y. Aksenov, M.V. Aksenova, D.A. Butterfield, K. Hensley, C. Vigo-Pelfrey, and J.M. Carney Glutamine synthetase-induced enhancement of beta-amyloid peptide A beta (1-40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation J. Neurochem. 66 1996 2050 2056 (Pubitemid 26118797)
125. M.Y. Aksenov, M.V. Aksenova, W.R. Markesbery, and D.A. Butterfield Amyloid beta-peptide (1-40)-mediated oxidative stress in cultured hippocampal neurons. Protein carbonyl formation, CK BB expression, and the level of Cu, Zn, and Mn SOD mRNA J. Mol. Neurosci. 10 1998 181 192 (Pubitemid 28427886)
126. S.M. Yatin, M. Aksenova, M. Aksenov, W.R. Markesbery, T. Aulick, and D.A. Butterfield Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses J. Mol. Neurosci. 11 1998 183 197 (Pubitemid 29232849)
127. S.M. Yatin, S. Varadarajan, and D.A. Butterfield Vitamin E prevents Alzheimer?s amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production J. Alzheimers Dis. 2 2000 123 131
128. D. Boyd-Kimball, R. Sultana, H.F. Poon, H. Mohmmad-Abdul, B.C. Lynn, J.B. Klein, and D.A. Butterfield Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1-42)-mediated oxidative stress in neuronal cell culture: a proteomics approach J. Neurosci. Res. 79 2005 707 713 (Pubitemid 40476450)
129. M.A. Ansari, H.M. Abdul, G. Joshi, W.O. Opii, and D.A. Butterfield Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer?s disease J. Nutr. Biochem. 20 2009 269 275
130. M.Y. Aksenov, M.V. Aksenova, J.M. Carney, and D.A. Butterfield Oxidative modification of glutamine synthetase by amyloid beta peptide Free Radic. Res. 27 1997 267 281 (Pubitemid 27474886)
131. D.A. Butterfield, K. Hensley, P. Cole, R. Subramaniam, M. Aksenov, M. Aksenova, P.M. Bummer, B.E. Haley, and J.M. Carney Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer?s disease J. Neurochem. 68 1997 2451 2457 (Pubitemid 27218166)
132. M. Aksenov, M. Aksenova, D.A. Butterfield, and W.R. Markesbery Oxidative modification of creatine kinase BB in Alzheimer?s disease brain J. Neurochem. 74 2000 2520 2527 (Pubitemid 30314229)
133. D. Boyd-Kimball, A. Castegna, R. Sultana, H.F. Poon, R. Petroze, B.C. Lynn, J.B. Klein, and D.A. Butterfield Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer?s disease Brain Res. 1044 2005 206 215 (Pubitemid 40693453)
134. R. Sultana, and D.A. Butterfield Alterations of some membrane transport proteins in Alzheimer?s disease: role of amyloid beta-peptide Mol. Biosyst. 4 2008 36 41 (Pubitemid 350261752)
135. E. Masliah, M. Alford, R. DeTeresa, M. Mallory, and L. Hansen Deficient glutamate transport is associated with neurodegeneration in Alzheimer? disease Ann. Neurol. 40 1996 759 766 (Pubitemid 26415188)
136. M.E. Harris, J.M. Carney, P.S. Cole, K. Hensley, B.J. Howard, L. Martin, P. Bummer, Y. Wang, N.W. Pedigo Jr.; and D.A. Butterfield Beta-amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer?s disease Neuroreport 6 1995 1875 1879
137. M.E. Harris, Y. Wang, N.W. Pedigo Jr, K. Hensley, D.A. Butterfield, and J.M. Carney Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures J. Neurochem. 67 1996 277 286 (Pubitemid 26185607)
138. R.J. Mark, K. Hensley, D.A. Butterfield, and M.P. Mattson Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death J. Neurosci. 15 1995 6239 6249
139. R. Sultana, and D.A. Butterfield Identification of the oxidative stress proteome in the brain Free Radic. Biol. Med. 50 2011 487 494
140. D.A. Butterfield, K. Hensley, M. Harris, M. Mattson, and J. Carney Beta-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer?s disease Biochem. Biophys. Res. Commun. 200 1994 710 715
141. R. Subramaniam, T. Koppal, M. Green, S. Yatin, B. Jordan, J. Drake, and D.A. Butterfield The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide(25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer?s disease Neurochem. Res. 23 1998 1403 1410 (Pubitemid 28500760)
142. A.J. Bruce-Keller, J.G. Begley, W. Fu, D.A. Butterfield, D.E. Bredesen, J.B. Hutchins, K. Hensley, and M.P. Mattson Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid beta-peptide J. Neurochem. 70 1998 31 39 (Pubitemid 28020825)
143. T. Koppal, R. Subramaniam, J. Drake, M.R. Prasad, H. Dhillon, and D.A. Butterfield Vitamin E protects against Alzheimer?s amyloid peptide (25-35)-induced changes in neocortical synaptosomal membrane lipid structure and composition Brain Res. 786 1998 270 273 (Pubitemid 28191745)
144. M.R. Prasad, M.A. Lovell, M. Yatin, H. Dhillon, and W.R. Markesbery Regional membrane phospholipid alterations in Alzheimer?s disease Neurochem. Res. 23 1998 81 88 (Pubitemid 28145695)
145. M. Mapstone, A.K. Cheema, and M.S. Fiandaca Plasma phospholipids identify antecedent memory impairment in older adults Nat. Med 20 2014 415 418
146. D.A. Butterfield, and J. Kanski Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer?s amyloid beta-peptide 1-42 Peptides 23 2002 1299 1309 (Pubitemid 34786708)
147. D.A. Butterfield, and D. Boyd-Kimball The critical role of methionine 35 in Alzheimer?s amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity Biochim. Biophys. Acta 1703 2005 149 156 (Pubitemid 40170438)
148. D.A. Butterfield, and R. Sultana Methionine-35 of abeta(1-42): importance for oxidative stress in Alzheimer disease J. Amino Acids 2011 2011 198430
149. J. Kanski, M. Aksenova, and D.A. Butterfield The hydrophobic environment of Met35 of Alzheimer?s Abeta(1-42) is important for the neurotoxic and oxidative properties of the peptide Neurotox. Res. 4 2002 219 223 (Pubitemid 34679372)
150. C. Schoneich Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer?s disease Biochim. Biophys. Acta 1703 2005 111 119 (Pubitemid 40170434)
151. S. Varadarajan, J. Kanski, M. Aksenova, C. Lauderback, and D.A. Butterfield Different mechanisms of oxidative stress and neurotoxicity for Alzheimer? Abeta(1-42) and Abeta(25-35) J. Am. Chem. Soc. 123 2001 5625 5631 (Pubitemid 32904694)
152. X. Huang, C.S. Atwood, M.A. Hartshorn, G. Multhaup, L.E. Goldstein, R.C. Scarpa, M.P. Cuajungco, D.N. Gray, J. Lim, R.D. Moir, R.E. Tanzi, and A.I. Bush The A beta peptide of Alzheimer?s disease directly produces hydrogen peroxide through metal ion reduction Biochemistry 38 1999 7609 7616 (Pubitemid 29289332)
153. C.W. Ritchie, A.I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q.X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R.E. Tanzi, and C.L. Masters Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch Neurol. 60 2003 1685 1691 (Pubitemid 37521621)
154. C.C. Curtain, F. Ali, I. Volitakis, R.A. Cherny, R.S. Norton, K. Beyreuther, C.J. Barrow, C.L. Masters, A.I. Bush, and K.J. Barnham Alzheimer?s disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits J. Biol. Chem. 276 2001 20466 20473
155. K. Hensley, J.M. Carney, M.P. Mattson, M. Aksenova, M. Harris, J.F. Wu, R.A. Floyd, and D.A. Butterfield A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease Proc. Natl. Acad. Sci. USA 91 1994 3270 3274
156. J. Kanski, M. Aksenova, C. Schoneich, and D.A. Butterfield Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer?s amyloid beta-peptide Free Radic. Biol. Med. 32 2002 1205 1211 (Pubitemid 34603357)
157. D.A. Butterfield, V. Galvan, M.B. Lange, H. Tang, R.A. Sowell, P. Spilman, J. Fombonne, O. Gorostiza, J. Zhang, R. Sultana, and D.E. Bredesen In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP Free Radic. Biol. Med. 48 2010 136 144
158. R. Sultana, R.A. Robinson, M.B. Lange, A. Fiorini, V. Galvan, J. Fombonne, A. Baker, O. Gorostiza, J. Zhang, J. Cai, W.M. Pierce, D.E. Bredesen, and D.A. Butterfield Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis? Antioxid. Redox Signal. 17 2012 1507 1514
159. R.B. Raffa, and R.J. Tallarida Chemo-fog. 2010 Landis Biosci. Press Austin
160. R.B. Raffa Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in ?chemo-fogchemo-brain? J. Clin. Pharm. Ther. 35 2010 1 9
161. S.K. Conroy, B.C. McDonald, D.J. Smith, L.R. Moser, J.D. West, L.M. Kamendulis, J.E. Klaunig, V.L. Champion, F.W. Unverzagt, and A.J. Saykin Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage Breast Cancer Res. Treat. 137 2013 493 502
162. M.B. de Ruiter, L. Reneman, W. Boogerd, D.J. Veltman, M. Caan, G. Douaud, C. Lavini, S.C. Linn, E. Boven, F.S. van Dam, and S.B. Schagen Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging Hum. Brain Mapp. 33 2012 2971 2983
163. B.C. McDonald, and A.J. Saykin Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations Brain Imaging Behav 7 2013 374 387
164. M. Simo, X. Rifa-Ros, A. Rodriguez-Fornells, and J. Bruna Chemobrain: a systematic review of structural and functional neuroimaging studies Neurosci. Biobehav. Rev. 37 2013 1311 1321
165. T.A. Ahles, and A.J. Saykin Candidate mechanisms for chemotherapy-induced cognitive changes Nat. Rev. Cancer 7 2007 192 201
166. P.A. Ganz, L. Kwan, S.A. Castellon, A. Oppenheim, J.E. Bower, D.H. Silverman, S.W. Cole, M.R. Irwin, S. Ancoli-Israel, and T.R. Belin Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance J. Natl. Cancer Inst. 105 2013 791 801
167. Y. Chen, P. Jungsuwadee, M. Vore, D.A. Butterfield St, and D.K. Clair Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues Mol. Interven 7 2007 147 156 (Pubitemid 47026725)
168. G. Joshi, R. Sultana, J. Tangpong, M.P. Cole, D.K. St Clair, M. Vore, S. Estus, and D.A. Butterfield Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain Free Radic. Res. 39 2005 1147 1154 (Pubitemid 41601416)
169. G. Joshi, C.D. Aluise, M.P. Cole, R. Sultana, W.M. Pierce, M. Vore, D.K. St Clair, and D.A. Butterfield Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain Neuroscience 166 2010 796 807
170. J. Tangpong, M.P. Cole, R. Sultana, G. Joshi, S. Estus, M. Vore, W. St Clair, S. Ratanachaiyavong, D.K. St Clair, and D.A. Butterfield Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity Neurobiol. Dis. 23 2006 127 139 (Pubitemid 44192385)
171. P. Jungsuwadee, M.P. Cole, R. Sultana, G. Joshi, J. Tangpong, D.A. Butterfield, D.K. St Clair, and M. Vore Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice Mol. Cancer Ther 5 2006 2851 2860 (Pubitemid 44849012)
172. P. Jungsuwadee, R. Nithipongvanitch, Y. Chen, T.D. Oberley, D.A. Butterfield St, D.K. Clair, and M. Vore Mrp1 localization and function in cardiac mitochondria after doxorubicin Mol. Pharmacol. 75 2009 1117 1126
173. C.D. Aluise, S. Miriyala, T. Noel, R. Sultana, P. Jungsuwadee, T.J. Taylor, J. Cai, W.M. Pierce, M. Vore, J.A. Moscow, D.K. St Clair, and D.A. Butterfield 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain Free Radic. Biol. Med. 50 2011 1630 1638
174. S.K. Dhar St, and D.K. Clair Manganese superoxide dismutase regulation and cancer Free Radic. Biol. Med. 52 2012 2209 2222
175. J. Tangpong, M.P. Cole, R. Sultana, S. Estus, M. Vore, W. St Clair, S. Ratanachaiyavong, D.K. St Clair, and D.A. Butterfield Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain J. Neurochem. 100 2007 191 201 (Pubitemid 46090774)
176. J.T. Keeney, S. Forster, R. Sultana, L.D. Brewer, C.S. Latimer, J. Cai, J.B. Klein, N.M. Porter, and D.A. Butterfield Dietary vitamin D deficiency in rats from middle to old age leads to elevated tyrosine nitration and proteomics changes in levels of key proteins in brain: implications for low vitamin D-dependent age-related cognitive decline Free Radic. Biol. Med. 65 2013 324 334
177. J.T. Keeney, A.M. Swomley, S. Forster, J.L. Harris, R. Sultana, and D.A. Butterfield Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration Proteomics Clin. Appl. 7 2013 109 122
178. M. Furlanut, and L. Franceschi Pharmacology of ifosfamide Oncology 65 Suppl. 2 2003 2 6 (Pubitemid 37346722)
179. Y. Zhang, J.D. Kawedia, A.L. Myers, C.M. McIntyre, P.M. Anderson, M.A. Kramer, and K.S. Culotta Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion J. Oncology Pharm. Pract 20 2014 51 57
180. C.D. Aluise St, D. Clair, M. Vore, and D.A. Butterfield In vivo amelioration of adriamycin induced oxidative stress in plasma by gamma-glutamylcysteine ethyl ester (GCEE) Cancer Lett. 282 2009 25 29
181. C.D. Aluise, R. Sultana, J. Tangpong, M. Vore, D. St Clair, J.A. Moscow, and D.A. Butterfield Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction Adv. Exp. Med. Biol. 678 2010 147 156